A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer.
The long-term survival benefit of lobectomy over sublobar resection for early-stage non-small cell lung cancer must be weighed against a potentially increased risk of perioperative mortality. The objective of the current study was to create a risk score to identify patients with favorable short-term outcomes following lobectomy.



The 2005-2012 American College of Surgeons National Surgical Quality Improvement Program database was queried for patients undergoing a lobectomy or sublobar resection (either segmentectomy or wedge resection) for lung cancer. A multivariable logistic regression model was utilized to determine factors associated with 30-day mortality among the lobectomy group and to develop an associated risk score to predict perioperative mortality.



Of the 5,749 patients who met study criteria, 4,424 (77%) underwent lobectomy, 1,098 (19%) underwent wedge resection, and 227 (4%) underwent segmentectomy. Age, chronic obstructive pulmonary disease, previous cerebrovascular event, functional status, recent smoking status, and surgical approach (minimally invasive versus open) were utilized to develop the risk score. Patients with a risk score of 5 or lower had no significant difference in perioperative mortality by surgical procedure. Patients with a risk score greater than 5 had significantly higher perioperative mortality after lobectomy (4.9%) as compared to segmentectomy (3.6%) or wedge resection (0.8%, p < 0.01).



In this study, we have developed a risk model that predicts relative operative mortality from a sublobar resection as compared to a lobectomy. Among patients with a risk score of 5 or less, lobectomy confers no additional perioperative risk over sublobar resection.
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Brian C
BC
Gulack
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Chi-Fu Jeffrey
CJ
Yang
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Paul J
PJ
Speicher
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Babatunde A
BA
Yerokun
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Betty C
BC
Tong
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Mark W
MW
Onaitis
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Thomas A
TA
D'Amico
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
David H
DH
Harpole
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Matthew G
MG
Hartwig
Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, California. Electronic address: berry037@stanford.edu.
Mark F
MF
Berry
D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D016015:Logistic Models; D008175:Lung Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018579:Patient Selection; D011013:Pneumonectomy; D012307:Risk Factors; D016896:Treatment Outcome